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Abstract: Brazil has an aging population, with an associated increase in the prevalence of 
chronic diseases. Postmenopausal osteoporosis is of particular concern because it leads to an 
increased risk of fractures, with subsequent negative impacts on health in older women. In recent 
years, efforts have been made to better understand the epidemiology of osteoporosis in Brazil, 
and to manage both direct and indirect costs to the Brazilian health care system. The reported 
prevalence of osteoporosis among postmenopausal women in Brazil varies from 15% to 33%, 
depending on the study methodology and the use of bone densitometry data or self-reporting 
by participants. A diagnosis of osteoporosis can be made on the basis of fractures occurring 
without significant trauma or on the basis of low bone mineral density measured by dual energy 
X-ray absorptiometry. To reduce the risk of osteoporosis, all postmenopausal women should 
be encouraged to maintain a healthy lifestyle, which includes physical activity and a balanced 
diet. Smoking and alcohol use should also be addressed. Special attention should be given to 
interventions to reduce the risk of falls, especially among older women. Calcium intake should 
be encouraged, preferably through diet. The decision to recommend calcium supplementation 
should be made individually because there is concern about a possible increased risk of cardio-
vascular disease associated with this treatment. Brazilian women obtain a minimal amount of 
vitamin D from their diet, and supplementation is warranted in women with little exposure to 
solar ultraviolet-B radiation. For women diagnosed with osteoporosis, some form of pharma-
cologic therapy should be initiated. Compliance with treatment should be monitored, and the 
treatment period should be individualized for each patient. The Brazilian government provides 
medication for osteoporosis through the public health system free of charge, but without proper 
epidemiological knowledge, the implementation of public health programs is impaired.
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Introduction
The Brazilian population has aged considerably over the past few decades. Data from the 
population census indicate an inversion of the national age pyramid. It is estimated 
that by the year 2050, the elderly will account for 23% of the population, and children 
aged 0–14 years will account for only 13% of the population.1 As a population ages, 
the epidemiology of disease changes. In the past, acute infectious diseases accounted 
for the vast majority of health problems. Currently, chronic diseases have an increas-
ingly important impact on the lives of the Brazilian people.2 Therefore, physicians 
should keep up to date with the management of the chronic diseases that are common 
in an aging population. Among these chronic diseases, postmenopausal osteoporosis 
is of particular importance because of its potentially harmful consequences to health 
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in elderly women and the fact that relatively simple treat-
ments can change the natural history of the disease.
Osteoporosis is a chronic disease, defined as a skeletal 
disorder characterized by decreased bone strength, which 
predisposes affected individuals to fractures.3 A diagnosis 
of osteoporosis can be made on the based of either fractures 
occurring without significant trauma or low bone mineral 
density measured by dual energy X-ray absorptiometry 
(DXA).4 Most women with osteoporosis are asymptomatic, 
which makes epidemiological research especially difficult. 
In Brazil, a large country with extremely diverse characteris-
tics from region to region, accurately determining the preva-
lence of osteoporosis is a complicated task. In recent years, 
efforts have been made to better understand the epidemiology 
of postmenopausal osteoporosis and to manage both the direct 
and the indirect costs of the disease to the Brazilian health 
care system.5 In this article, we review recent studies of the 
epidemiology and management of postmenopausal osteopo-
rosis, with a particular focus on the situation in Brazil.
Epidemiology of osteoporosis 
in Brazil
The reported prevalence of postmenopausal osteoporosis in 
Brazil is highly variable because of differences in the study 
methodology, the selection of study participants, and the 
definition of the disease. In a study by Camargo et al6 pub-
lished in 2005, which included 207 women aged .70 years, 
osteoporosis was diagnosed by bone densitometry and classi-
fied according to World Health Organization (WHO) criteria. 
The prevalence of osteoporosis ranged from 22.2% to 33.2%, 
depending on the bone evaluated.6 A study by Martini et al7 
published in 2009, used data from a telephone survey on 
chronic diseases (Vigilância de fatores de risco e proteção 
para doenças crônicas por inquérito telefônico [Protective 
and Risk Factors for Chronic Diseases by Telephone Sur-
vey]). Interviews were conducted with 54,369 individuals 
aged $18 years, and the presence of osteoporosis was 
determined on the basis of self-reporting by participants. 
The prevalence of osteoporosis was 8% in women aged 
45–54 years, 19.2% in women aged 55–64 years, and 32.7% 
in women .65 years.7 In 2010, Pinheiro et al8 published the 
results of a household survey, the Brazilian Osteoporosis Study 
(BRAZOS), which included a representative sample of women 
from all regions of Brazil. Again, the diagnosis of osteoporosis 
was based on self-reporting by participants. In this survey, 
1,695 women aged .40 years were interviewed, and of these 
approximately 35% were premenopausal. For postmenopausal 
women, the average age of the last menstrual period was 
47±5.1 years. The prevalence of osteoporosis was reported 
as 15.1%.8 In 2010, Pinheiro et al9 also conducted a cross-
sectional study that included 4,332 women aged .40 years 
in São Paulo (São Paulo Osteoporosis Study [SAPOS]). 
The diagnosis of osteoporosis was made by DXA, and the 
prevalence of postmenopausal osteoporosis was 33%.9 In 2011, 
Buttros et al10 reported a prevalence of 24.6% from a cross-
sectional study of 431 women aged 40–75 years with osteo-
porosis diagnosed by DXA. More recently, in 2013, Baccaro 
et al11 published the results of a population-based household 
survey that included 622 women aged .50 years. The preva-
lence of osteoporosis based on self-reporting was 21.3%, but 
only 16.7% of the participants reported that the diagnosis of 
osteoporosis had been made by bone densitometry.
As demonstrated by these studies, the prevalence of 
osteoporosis in Brazil varies widely according to the study 
methodology. Some studies based the diagnosis of osteo-
porosis on bone densitometry data and others relied on 
self-reporting by participants. Furthermore, there are few 
studies that include a representative sample of the population 
from all regions of the country. Overall, depending on age 
and the characteristics of the study population, the reported 
prevalence of osteoporosis in Brazilian women varies from 
15% to 33%. A recent study on the epidemiology of osteo-
porosis in the United States found a prevalence of 15.4% 
among women older than 50 years and a prevalence of 34.9% 
among women older than 80 years.12 Therefore, despite the 
limitations related to a lack of uniformity of national studies, 
the percentage of Brazilian women living with osteoporosis 
appears to be similar to that in other populations.
Factors associated with 
postmenopausal osteoporosis
Recent national studies have identified some of the factors 
associated with osteoporosis among Brazilian women. In 
their study published in 2009, Martini et al7 reported a posi-
tive association between osteoporosis and age .45 years, not 
being single, height in the third quartile, and being a former 
smoker. Women with higher education and those who were not 
white had a lower prevalence of osteoporosis.7 In the SAPOS 
study, the main factors associated with low bone mineral 
density were advanced age, menopause, a history of prior 
fracture, and being a smoker. Women with a higher body mass 
index who performed regular physical activity and received 
hormone replacement therapy had a lower prevalence of low 
bone mineral density.9 Recently, Baccaro et al11 reported that 
osteoarthritis, a longer time since menopause, balance prob-
lems, impaired functional capacity, and poorer self-perception 
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of health were associated with a higher prevalence of osteopo-
rosis. In the same study, presenting with poorer self-perception 
of health, treatment with natural remedies for menopause, 
smoking more than one pack of cigarettes per day (currently 
or in the past), and impaired functional capacity were factors 
associated with early onset of the disease.11
A number of dietary factors are known to be associ-
ated with decreased bone mineral density. A low intake of 
calcium can lead to increased resorption of the bone matrix 
with demineralization and a consequent increase in frac-
ture risk. International societies recommend a daily intake 
of calcium of 1,200–2,000 mg per day.13 However, many 
Brazilian women do not have an adequate dietary calcium 
intake. Data from the BRAZOS study indicated that the 
average daily calcium intake among Brazilian women was 
approximately 400 mg per day, which may contribute to an 
increase in the frequency of diseases resulting from bone 
demineralization.14
Vitamin D is a prosteroid hormone that plays an essential 
role in the metabolism of calcium and phosphate. Through stim-
ulation of intestinal absorption of these elements, vitamin D 
contributes to the maintenance of adequate levels of serum 
calcium, and consequently to bone mineralization.15 It can 
be obtained exogenously through the diet, for example, from 
wild saltwater fish like salmon, but it is primarily produced 
endogenously by the action of solar ultraviolet-B radiation 
on the skin.16 Brazil extends from the equatorial latitudes in 
the north to the temperate latitudes in the south, with a large 
variation in sunlight levels across the country. In the south 
and southeast regions, which have the highest demographic 
densities in the country, levels of solar radiation are lower 
during fall and winter. This regional feature could lead to a 
higher prevalence of vitamin D deficiency, contributing to 
the development of low bone mineral density and osteopo-
rosis. In 2013, Arantes et al17 published a study that included 
1,933 postmenopausal women living in six large Brazilian 
cities, with a variation of 25 degrees of latitude between the 
northernmost city (Recife) and the southernmost city (Porto 
Alegre). The prevalence of vitamin D deficiency was high. 
When analyzed together, 17% of women had vitamin D 
levels ,20 ng/mL and 68.3% had vitamin D levels ,30 ng/mL. 
Women living in cities located further north (Recife and 
Salvador) had significantly higher levels of 25-hydroxy 
vitamin D compared with women who lived in cities in south-
ern Brazil (Rio de Janeiro, São Paulo, Curitiba, and Porto 
Alegre). The authors concluded that, on average, there was 
a decrease of 0.28 ng/mL in 25-hydroxy vitamin D level for 
each degree of latitude further south. This higher prevalence 
of vitamin D deficiency may be associated with a higher 
frequency of osteoporosis and bone fractures, although this 
study found no significant relationship between vitamin D 
levels and bone mineral density at the femoral neck and 
lumbar spine.17
Diagnostic methods
Postmenopausal osteoporosis can be diagnosed on the basis 
of clinical history alone, when a symptomatic bone fracture 
results from low-intensity trauma.4 However, in most cases, 
imaging tests are needed to identify a decrease in bone 
mineral density or asymptomatic vertebral fractures.18 The 
criteria for the classification of osteoporosis published by the 
WHO may be used for postmenopausal women (Table 1). 
The bone locations recommended for evaluation by bone 
densitometry are the lumbar spine, total hip, and femoral 
neck. The evaluation of the one-third radius site can be used 
for classification when measurements of the lumbar spine 
and proximal femur are unavailable.19
The consensus of international and Brazilian guidelines is 
to perform bone densitometry for all women aged $65 years. 
For younger postmenopausal women, or women in the peri-
menopause, bone densitometry is only indicated for those with 
additional risk factors or conditions that are associated with a 
higher incidence of fractures.18,20,21 However, a recent study 
including 445 postmenopausal women aged 50–64 years 
found that the recommendations of the United States 
Preventive Services Task Force, one of the most widely 
used guidelines to determine the use of bone densitometry 
examination in the United States and similar to the Brazilian 
consensus, had a sensitivity of only 24%. In other words, it 
is possible that many younger postmenopausal women with 
osteoporosis are not diagnosed in a timely manner.22 In Brazil, 
a mathematical tool that identifies women at higher risk of 
low bone mineral density and fragility fractures could help 
to identify women for bone densitometry screening.23
In 2002, the Brazilian Ministry of Health issued a 
decree to gain a better understanding of the national avail-
ability of diagnostic imaging equipment, including bone 
densitometers.24 According to this decree, 7.1 densitometers 
Table 1 World Health Organization’s definition of osteoporosis 
based on bone mineral density
Classification T-score
Normal $−1.0
Low bone mass (osteopenia) Between −1.0 and −2.5
Osteoporosis #−2.5
Severe or established osteoporosis #−2.5 with one or more fractures
Note: Data from Kanis et al.19
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per 1 million inhabitants should be available for the popu-
lation. However, according to a study conducted by the 
Brazilian Institute of Geography and Statistics (IBGE) in 
2009,25 there are 5.6 densitometers per 1 million inhabitants, 
taking into account both public and private sectors. In the 
public sector, there are only 1.5 densitometers per 1 million 
inhabitants. In 2012, Hernandez et al26 published the results 
of a prospective study of 2,143 people aged $60 years 
living in São Paulo. Among women who had private health 
insurance (51.3% of the study population), 65.7% reported 
having osteoporosis. Among women who relied primar-
ily on the public health system, 34.3% reported having 
osteoporosis.26 These data suggest that women with private 
health insurance have greater availability of resources for 
the diagnosis of osteoporosis. However, women who are 
dependent on the public health system do not have sufficient 
access to densitometers, which can lead to delayed or missed 
diagnosis of osteoporosis.
Performing radiography of the spine is also of critical 
importance for patients with risk factors for osteoporosis 
because the presence of asymptomatic vertebral fractures 
significantly increases the risk of new vertebral and femoral 
neck fractures,27 and can change the therapeutic approach, 
especially in patients who present with osteopenia. Spinal 
radiographs should be performed for women who have 
lost $2.5 cm in height over a period of 2 years with associ-
ated pain or deformity in the spine, as well as for individuals 
with chronic use of glucocorticoids.28
Treatment
All postmenopausal women should be encouraged to main-
tain a healthy lifestyle, which includes physical activity and a 
balanced diet. Additionally, smoking and alcohol use should 
be addressed, because both are known risk factors for low 
bone mineral density. Special attention should be given to 
interventions to reduce the risk of falls in postmenopausal 
women, especially among older women with osteoporosis. 
Supervised exercise programs and measures to improve home 
safety, such as avoiding slippery rugs, stairs, and environ-
ments with low light, are known to reduce the risk of falls 
in the elderly.29
Adequate calcium intake should be encouraged in 
postmenopausal women, preferably through diet. Because 
calcium supplementation has a beneficial effect on bone 
mineral density, mineral supplements can be used in patients 
who do not have adequate nutrition. Calcium supplementa-
tion may also reduce the incidence of vertebral fractures, 
but its effects on the incidence of nonvertebral fractures 
remains uncertain.30 Recently, there has been concern about 
a possible increased risk of cardiovascular disease related 
to the use of calcium supplements. In 2010, Bolland et al31 
published a meta-analysis that identified a 31% increase in 
the risk of myocardial infarction among patients receiving 
calcium supplementation ($500 mg/d).31 However, another 
systematic review and meta-analysis found no association 
between calcium supplementation and an increased risk of 
cardiovascular disease.32 Results from the Nurses’ Health 
Study,33 a large prospective cohort study of 74,245 women 
followed for 24 years, found no association between the use 
of calcium supplements and an increased risk of cardiovas-
cular disease. In fact, women who used calcium supplements 
had a lower incidence of ischemic heart disease.33 There-
fore, the decision to recommend calcium supplementation 
should be made individually, taking into account individual 
dietary habits.
In addition to low levels of dietary calcium, Brazilian 
women obtain a minimal amount of vitamin D from their diet. 
Foods that are rich sources of vitamin D are not accessible to 
most women in Brazil, and currently, there are no vitamin D 
food fortification policies.14 Supplementation is warranted in 
patients with little exposure to solar ultraviolet-B radiation. 
Serum 25-hydroxy vitamin D levels are useful to determine 
reserves of vitamin D and to plan doses for supplementation. 
The Institute of Medicine (IOM) in the United States consid-
ers levels of 25-hydroxy vitamin D $20 ng/mL sufficient 
to maintain bone mineral density.13 The Brazilian Society of 
Endocrinology and Metabolism is stricter and considers the 
adequate level to be $30 ng/mL.34 For patients with very low 
levels of 25-hydroxy vitamin D (,20 ng/mL), administration 
of 7,000 international units (IU) per day or 50,000 IU per 
week for up to 2 months is recommended.35 According to the 
Brazilian Society of Endocrinology and Metabolism, women 
with osteoporosis should maintain levels of 25-hydroxy 
vitamin D .30 ng/mL and should take vitamin D supple-
mentation of between 1,000 and 2,000 IU per day.34
For women diagnosed with osteoporosis, some form of 
pharmacologic therapy should be initiated. For those with 
densitometry values compatible with osteopenia, individual 
risk factors for fracture should be considered to guide treat-
ment decisions. The Fracture Risk Assessment Tool (FRAX) 
developed by the WHO is now available for use in the Bra-
zilian population,36 although there is no national consensus 
on the risk thresholds that should indicate initiation of 
drug therapy. A previous study showed that the association 
between age and densitometry values is as effective as the 
FRAX model to identify individuals at high risk of bone 
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fracture.37 New studies on the use of the FRAX tool are 
needed before it can be used to guide decisions on whether 
or not to initiate drug therapy for Brazilian women.
Drugs with different mechanisms of action are avail-
able to treat postmenopausal osteoporosis. Among them are 
the bisphosphonates, hormone replacement therapy with 
estrogen, selective estrogen receptor modulators, calcitonin, 
strontium ranelate, denosumab, and teriparatide. The main 
characteristics of these drugs are described in Table 2.
The Brazilian Federal Government, through the public 
health system (Sistema Único de Saúde [SUS]), provides 
free medication through public policies aimed at ensuring the 
integrity of pharmacological treatment. To qualify for free 
medication, candidates for drug therapy must meet certain 
clinical criteria (Table 3). For postmenopausal women, there 
is a flow chart with the medications available free of charge 
through the SUS, and a suggested sequence for the use of 
these medications.20 All women should have an adequate 
intake of calcium and vitamin D, and supplementation should 
be performed if diet is not adequate. Bisphosphonates are 
the first-line treatment for diagnosed osteoporosis. The oral 
bisphosphonates alendronate and risedronate should be used 
first. For women who are intolerant to oral bisphosphonates, 
the use of intravenous pamidronate is recommended. Ral-
oxifene or conjugated estrogens can be used when there is a 
contraindication or intolerance to the use of bisphosphonates. 
In women with contraindications to the use of bisphospho-
nates, raloxifene, and estrogen conjugates, the use of calcitonin 
is recommended (Figure 1). Other medications that act on bone 
metabolism, such as teriparatide, zoledronic acid, ibandronate, 
strontium ranelate, and denosumab, are not provided free of 
charge by the SUS, because, according to the Clinical Protocol 
and Therapeutic Guidelines of the Ministry of Health, there 
is no evidence that these drugs are clinically superior to those 
covered by the Brazilian government program.20
Analysis of the management 
of osteoporosis in Brazil
National data indicate that approximately 75% of the Brazilian 
population do not have private health insurance and rely on 
the public health system (the SUS).58 Drug treatment for 
osteoporosis can decrease the morbidity and mortality of 
the disease and can decrease costs resulting from fractures 
caused by low-impact trauma. Brandão et al59 analyzed data 
Table 2 Drugs available to treat postmenopausal osteoporosis in Brazil
Main effects
Bisphosphonates
Alendronate Reduces the incidence of spinal and femoral fractures by approximately 50% over 3 years in patients with a history  
of prior vertebral fracture.38
Reduces the incidence of vertebral fracture by 44% in patients without a history of prior vertebral fracture.39
Risedronate Reduces the risk of vertebral fractures by 41%–49% and nonvertebral fractures by 33%–39% in patients with previous 
fractures.40
Ibandronate Reduces the incidence of vertebral fractures by approximately 50% over 3 years.41
Meta-analyses suggest that it is effective in reducing nonvertebral fractures.42
Pamidronate Used intravenously has similar efficacy to alendronate in improvement in bone mineral density at lumbar spine.43
effective in reducing bone loss after solid organ transplantation and in chronic users of corticoids.20
“Off-label” use for osteoporosis treatment.
Zoledronic acid Reduces the risk of vertebral fractures by 70%, femoral neck fractures by 41%, and nonvertebral fractures by 25%.44
Hormone therapy  
with estrogen
Reduces the risk of clinical vertebral fractures and hip fractures by 34% and other osteoporotic fractures by 23%.45
Raloxifene Reduces the risk of vertebral fractures in women with osteopenia or osteoporosis by 30%–50%.46–49
Does not diminish the risk of nonvertebral fractures.
Reduces the risk of invasive estrogen-dependent breast cancer in postmenopausal women with osteoporosis50,51  
and/or at high risk of breast cancer.52
Calcitonin Reduces the risk of vertebral fractures by 33% in patients without previous fractures.53
Reduces the risk of new vertebral fractures by 36% in patients who already have a history of vertebral fracture.53
Does not reduce the risk of nonvertebral fractures.53
Teriparatide Reduces the incidence of vertebral fractures by approximately 65% and of nonvertebral fractures by approximately 53%.54
Because there is a theoretical risk of osteosarcoma, the medication should be used for a maximum of 2 years.54
Denosumab Patients with osteoporosis who received denosumab for 3 years experienced a 68% reduction in the risk of new  
vertebral fractures, a 20% reduction in nonvertebral fractures, and a 40% reduction in femoral neck fractures.55
Strontium ranelate Reduces the risk of a new vertebral fracture by 49% after 1 year of treatment and by 41% after 3 years of treatment  
in women with a prior vertebral fracture.56
Reduces the risk of vertebral fractures in women without a history of previous fractures by 45%, and the risk  
of nonvertebral fractures by 16%.57
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from a historical cohort of 72,265 women using medications 
provided by the SUS for postmenopausal osteoporosis 
between the years 2000 and 2006. The average monthly 
per capita expenditure in the first year of treatment was 
approximately USD54.00, and most women used the same 
medication throughout the treatment period (89.8%). Alen-
dronate was the most commonly used drug at the initiation 
of therapy (57.0%), followed by calcitonin (24.6%), and 
raloxifene (15.6%). Risedronate had a low frequency of use 
(0.4%). With regard to costs, raloxifene and calcitonin were 
associated with the greatest expenses for the SUS.59
Recently, Moraes et al60 published an article provid-
ing data on the expenditure of the Ministry of Health of 
Brazil for the treatment of osteoporosis during 2008–2010. 
It was found that women, who more frequently receive 
osteoporosis-related procedures and treatment, incur higher 
absolute costs than men. Women underwent 295,935 bone 
densitometry tests within the public health system in the 
3-year period, representing a total expenditure of approxi-
mately USD8,605,000. Women also accounted for most 
of the drug expenditure for osteoporosis during the study 
period, accounting for approximately USD34,035,000, and 
representing 97.8% of the total drug expenditure for osteopo-
rosis from 2008 to 2010. However, when the total spending 
on osteoporosis was adjusted for the number of procedures 
performed, men incurred a higher average cost per procedure. 
Most of the procedures in men were highly complex, which 
may indicate a delay in the diagnosis and treatment of the 
disease in the male population in Brazil.60
Monitoring of treatment
Monitoring the effectiveness of osteoporosis treatment is very 
important, especially in Brazil, where national studies show 
that women have difficulty adhering to prescribed medication 
Table 3 Criteria for the initiation of medical treatment for postmenopausal osteoporosis
Low-impact fracture of the femur, hip, or vertebrae (clinical or morphometric) radiologically confirmed
T-score #−2.5 at femoral neck or spine
Low bone mass (T-score between −1.5 and −2.5 at the femoral neck or spine) in patients aged 70 years or more if they have suffered two or more 
falls in the last 6 months
Glucocorticoid treatment in a dose higher than 5 mg of prednisone per day (or equivalent dose of another corticosteroid) for a period of 3 months or more
Notes: Data from Ministério da Saúde.20
Calcium and
vitamin D
supplementation
Contraindication to
bisphosphonates?
Alendronate or
risedronate
(pamidronate
if intolerant to oral
medication)
Contraindication to
raloxifene or hormone
therapy with estrogen?
Calcitonin Vasomotorsymptoms?
Hormone therapy
with estrogen* Raloxifene
No Yes
Yes No
Yes No
Figure 1 Flow chart with the medications available free of charge through SUS.
Note: *women with an intact uterus should make use of an estrogen and progesterone association.
Abbreviation: SUS, Sistema Único de Saúde.
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regimens, which may limit the effectiveness of medications. 
It is estimated that 61.3% of women do not make proper use 
of calcium and/or vitamin D supplements,61 and that 62.4% 
do not use weekly bisphosphonates correctly.62 Bone densi-
tometry is the gold standard to monitor bone mineral density. 
In patients receiving drug treatment for postmenopausal 
osteoporosis, densitometry should generally be repeated every 
2 years. In cases of severe osteoporosis and in patients with 
a high risk of new fractures, this interval can be reduced, but 
there should not be less than 1 year between each examina-
tion. Annual height measurement can also be used to monitor 
women with postmenopausal osteoporosis. Loss of $2 cm in 
height could mean that a new vertebral fracture has occurred, 
indicating the need for repeat spinal radiography.18
Duration of treatment
The duration of each form of treatment should be individual-
ized for each patient. As life expectancy increases, women 
will have to live for more years with osteoporosis and an 
increased risk of fragility fractures. Achieving a balance 
between the beneficial therapeutic effects and potential 
adverse effects arising from treatment is an ongoing chal-
lenge. Despite being the most frequently used agents, the use 
of bisphosphonates beyond 5 years is controversial. There is 
concern that prolonged use can cause a decrease in the ability 
of bone to remodel, resulting in damage to its microstructure. 
Such damage could lead to serious adverse events, such as 
subtrochanteric and shaft fractures,18 but this hypothesis has 
not yet been confirmed in randomized controlled trials. The 
occurrence of osteonecrosis of the jaw in patients receiving 
bisphosphonates is a very rare adverse event that occurs 
more frequently in women with cancer receiving high doses 
of intravenous bisphosphonates. Causality has not been 
established between the use of oral bisphosphonates and 
an increased incidence of osteonecrosis of the jaw.63 After 
5 years of use, the risk of fractures should be reassessed 
by clinical history, radiography, and bone densitometry to 
define the best approach to future treatment. In Brazil, it is 
recommended that women who have worsening of bone mass 
during treatment, or T-score values of −3.5 or less should 
continue to receive bisphosphonate therapy even after 5 years 
of initial use.20 In patients at high risk of bone fractures, the 
use of bisphosphonates for up to 10 years appears to be a 
favorable approach in terms of risks and benefits.64
Conclusion
Postmenopausal osteoporosis is a chronic and often 
asymptomatic disease. The prevalence in Brazil does not 
differ from that in other countries, but there is limited 
knowledge about the epidemiology of the disease. More 
population-based studies with rigorous methodology are 
necessary, preferably using bone densitometry to classify 
osteoporosis and with representative sample populations 
from all regions of the country. The Brazilian govern-
ment provides medication for osteoporosis through the 
public health system free of charge, but without proper 
epidemiological knowledge, the implementation of public 
health programs is impaired. In addition, conscientization 
programs for health professionals about the importance of 
osteoporosis would also be beneficial. If not diagnosed and 
treated properly, postmenopausal osteoporosis can result in 
bone fractures, which have negative impacts for both the 
patient and the health care system. Efforts are needed to 
ensure that all women in Brazil have access to information 
on osteoporosis and the opportunity to receive diagnosis 
and treatment for the disease.
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